BUSINESS AREA
Labtech
Companies in the Labtech business area are active in the market areas diagnostics, biomedical research and laboratory equipment.
| 3 months ending | 9 months ending | 12 months ending | ||||||
|---|---|---|---|---|---|---|---|---|
| SEKM | 30 Sep 24 | 30 Sep 23 | change | 30 Sep 24 | 30 Sep 23 | change | 30 Sep 24 | 31 Dec 23 |
| Net sales | 852 | 827 | 3% | 2,656 | 2,604 | 2% | 3,706 | 3,654 |
| Organic growth, % | 3% | 9% | 2% | 9% | 10% | |||
| EBITA | 76 | 99 | -23% | 284 | 321 | -12% | 436 | 473 |
| EBITA-margin | 8.9% | 12.0% | 10.7% | 12.3% | 11.8% | 12.9% | ||
Labtech's net sales increased by 3 percent in the third quarter to SEK 852m (827). The organic sales growth amounted to 3 percent and the acquired growth amounted to 3 percent. Exchange rate changes had a negative impact of 3 percent on net sales. EBITA decreased by 23 percent to SEK 76m (99), corresponding to an EBITA-margin of 8.9 percent (12.0). EBITA the previous year was positively affected by the reversed contingent consideration of SEK 15m. Adjusted for this, the EBITA-margin last year was 10.2%
Labtech's net sales increased by 2 percent in the interim period to SEK 2,656m (2,604), whereof the organic sales growth amounted to 2 percent and the acquired growth amounted to 1 percent. Exchange rate changes had a negative impact of 1 percent on net sales. EBITA decreased by 12 percent to SEK 284m (321), corresponding to an EBITA-margin of 10.7 percent (12.3).
Sales increased by 3 percent organically in the third quarter, which is typically the quarter with the lowest activity during the year. The sales of consumables have a high degree of stability in both diagnostics and research, and this was also the case during the third quarter. However, instrument sales were lower due to fewer procurement decisions and installations occurring during the summer. Additionally, staff shortages in procurement departments, uncertainty regarding research budgets, and slower sales growth for newly launched products negatively impacted instrument sales in the quarter. The assessment remains that instrument sales are delayed, not cancelled.
Demand from pharmaceutical companies remains strong, resulting in an increasing share of sales going to pharmaceutical companies while the share of sales to academic research decreases.
The weaker sales of more advanced instruments for research purposes, in particular, also had a negative effect on the margin in the quarter.
Several important tenders were secured during the third quarter, with deliveries expected to start in the fourth quarter.
In Eastern Europe, invoicing in the third quarter was weaker, similar to last year, with an expectation of a strong finish to the year.
|
Dynamisk graf: Net sales (SEKm)
|
Dynamisk graf: Net sales per market 2024
|
|
Dynamisk graf: EBITA (SEKm)
|
Dynamisk graf: EBITA-margin (%)
|